219 related articles for article (PubMed ID: 23994799)
1. Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan.
Yasuda H
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):209-16. PubMed ID: 23994799
[TBL] [Abstract][Full Text] [Related]
2. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
Yasuda H
Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
[TBL] [Abstract][Full Text] [Related]
3. [Updates of denosumab, anti-RANKL antibody for osteoporosis].
Tokuyama N; Tanaka S
Clin Calcium; 2014 Jan; 24(1):85-91. PubMed ID: 24369284
[TBL] [Abstract][Full Text] [Related]
4. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
5. Discovery of the RANKL/RANK/OPG system.
Yasuda H
J Bone Miner Metab; 2021 Jan; 39(1):2-11. PubMed ID: 33389131
[TBL] [Abstract][Full Text] [Related]
6. [Animal models for bone and joint disease. RANKL-injected bone loss model].
Yasuda H
Clin Calcium; 2011 Feb; 21(2):197-208. PubMed ID: 21289416
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
8. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
9. [Osteoporosis and RANKL signal].
Nakamura M; Udagawa N
Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Yoneda T
Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
[TBL] [Abstract][Full Text] [Related]
11. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
Maldonado-Gonzales E; Pietschmann P
Wien Med Wochenschr; 2010 Sep; 160(17-18):458-63. PubMed ID: 20714812
[TBL] [Abstract][Full Text] [Related]
12. RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
[TBL] [Abstract][Full Text] [Related]
13. Skeletal and extraskeletal actions of denosumab.
Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
[TBL] [Abstract][Full Text] [Related]
14. Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns.
Okamatsu N; Sakai N; Karakawa A; Kouyama N; Sato Y; Inagaki K; Kiuchi Y; Oguchi K; Negishi-Koga T; Takami M
Biochem Biophys Res Commun; 2017 Sep; 491(3):614-621. PubMed ID: 28760341
[TBL] [Abstract][Full Text] [Related]
15. [Development and pharmacological effects of anti-RANKL monoclonal antibody drug denosumab].
Takami M
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(3):162-9. PubMed ID: 23812074
[TBL] [Abstract][Full Text] [Related]
16. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
17. [Discovery of RANKL and the current and future impact of its research].
Yasuda H
Nihon Yakurigaku Zasshi; 2023; 158(3):247-252. PubMed ID: 37121707
[TBL] [Abstract][Full Text] [Related]
18. [Osteoporosis treatment by anti-RANKL antibody].
Sugimoto T
Clin Calcium; 2011 Aug; 21(8):1209-15. PubMed ID: 21814027
[TBL] [Abstract][Full Text] [Related]
19. [Denosumab - a new option in the treatment of osteoporosis].
Franek E
Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021
[TBL] [Abstract][Full Text] [Related]
20. Influence of RANKL inhibition on immune system in the treatment of bone diseases.
Fouque-Aubert A; Chapurlat R
Joint Bone Spine; 2008 Jan; 75(1):5-10. PubMed ID: 17920324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
